Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)
Eydenzelt® a biosimilar referencing Eylea®, receives a Notice of Compliance from Health Canada (aflibercept 2mg) The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global Phase III studies demonstratin
(Financial Post, 2025-11-27T23:59:21Z)